Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18484956 | 0.86 | KMT2A (0.36) | KMT2AMEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22877566 | 0.83 | KMT2A (0.34) | KMT2AMEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL26593066 | 0.83 | MAPK1 (0.35) | — | |
| SCHEMBL20144578 | 0.82 | TP53 (0.37) | KMT2A | |
| SCHEMBL24604509 | 0.82 | KMT2A (0.33) | KMT2AMEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22965794 | 0.82 | CYP1A2 (0.35) | KMT2AMEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22803191 | 0.82 | KMT2A (0.33) | KMT2AMEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22877565 | 0.81 | KMT2A (0.31) | KMT2AMEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL24482751 | 0.81 | KMT2A (0.33) | KMT2AMEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL25445949 | 0.79 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | CD47, MCL1, BCL9 | KMT2A 254/4885MEN1 2879/4885CYP2D6 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.